Format

Send to

Choose Destination
Oncoimmunology. 2016 Jun 24;5(8):e1203498. doi: 10.1080/2162402X.2016.1203498. eCollection 2016 Aug.

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.

Author information

1
Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland.

Abstract

Carcinoembryonic antigen T cell bispecific antibody (CEA TCB) is a bispecific antibody used to recognize CEA and CD3e via a novel molecular format (2:1) that induces T cell-mediated killing of CEA over-expressing tumors while sparing primary cells with low CEA expression. CEA TCB treatment inhibits tumor growth and generates a highly inflamed tumor microenvironment.

KEYWORDS:

Bispecific; T cell

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center